Aprea Therapeutics (NASDAQ:APRE – Get Free Report) will be posting its quarterly earnings results on Thursday, March 28th.
Aprea Therapeutics Trading Down 2.7 %
Shares of NASDAQ:APRE opened at $5.92 on Wednesday. Aprea Therapeutics has a 12 month low of $2.78 and a 12 month high of $8.85. The stock has a market cap of $22.14 million, a P/E ratio of -1.48 and a beta of 1.05. The company has a 50 day moving average of $6.35 and a 200 day moving average of $4.97.
Wall Street Analyst Weigh In
Separately, HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Aprea Therapeutics in a research note on Tuesday.
Insider Activity at Aprea Therapeutics
In other Aprea Therapeutics news, Director Bernd R. Seizinger bought 6,860 shares of Aprea Therapeutics stock in a transaction dated Wednesday, March 13th. The shares were purchased at an average cost of $7.29 per share, with a total value of $50,009.40. Following the completion of the purchase, the director now owns 33,685 shares of the company’s stock, valued at $245,563.65. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders have acquired a total of 9,870 shares of company stock worth $71,952 in the last 90 days. Company insiders own 20.90% of the company’s stock.
Institutional Investors Weigh In On Aprea Therapeutics
Several hedge funds have recently bought and sold shares of APRE. BNP Paribas Arbitrage SNC purchased a new position in shares of Aprea Therapeutics in the 3rd quarter worth about $40,000. Millennium Management LLC lifted its stake in shares of Aprea Therapeutics by 35.7% in the fourth quarter. Millennium Management LLC now owns 164,626 shares of the company’s stock worth $53,000 after buying an additional 43,293 shares in the last quarter. Jane Street Group LLC purchased a new stake in shares of Aprea Therapeutics during the second quarter valued at approximately $54,000. Geode Capital Management LLC bought a new stake in shares of Aprea Therapeutics during the second quarter valued at approximately $74,000. Finally, Vanguard Group Inc. raised its holdings in Aprea Therapeutics by 76.4% in the 3rd quarter. Vanguard Group Inc. now owns 27,341 shares of the company’s stock worth $114,000 after acquiring an additional 11,840 shares during the last quarter. Institutional investors own 34.19% of the company’s stock.
Aprea Therapeutics Company Profile
Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers.
Read More
- Five stocks we like better than Aprea Therapeutics
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- 3 Stocks With Unusual Call Option Activity
- Buy P&G Now, Before It Sets A New All-Time High
- Trump Media & Technology Group Soars on Market Debut
- What is a SEC Filing?
- 3 Stocks Insiders Are Buying That Analysts Love
Receive News & Ratings for Aprea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aprea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.